BEIJING, Feb. 27, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a fully integrated, China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release fourth quarter and full year 2011 financial results on Wednesday, March 14, 2012 after the market closes.
The Company will hold a conference call at 8:00 a.m. ET on Thursday, March 15, 2012 to discuss fourth quarter and full year 2011 results. Listeners may access the call by dialing:
| United States toll free: | 1-855-500-8701 |
| United States toll: | 1-646-254-3515 |
| China toll free: | 400-1200654 |
| Hong Kong toll free: | 800-903737 |
| United Kingdom toll free: | 0800-0159724 |
| Conference ID: | 57093004 |
A telephone replay will become available beginning two hours after the conclusion of the call and will remain available through March 28, 2012. Listeners may access the replay by dialing:
| United States toll free: | 1-866-214-5335 |
| International: | 1-718-354-1232 |
| Conference ID: | 57093004 |
A webcast will also be available through the Company's website www.nkbp.com.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a fully integrated, China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,900 hospitals in China. Nuokang's principal products include (i) Baquting®, the Company's flagship bleeding control product, (ii) Kaitong®, the lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis, (iii) Aiduo®, the cardiovascular stress imaging agent and (iv) Aiwen®, the anti-arrhythmic agent. Please visit www.nkbp.com for more information.